Sensorion reports first half 2024 results and highlights recent updates

Regulatory news:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore, treat and prevent hearing loss disorders, today reports its half-year results ended June 30, 2024 and its outlook for the remainder of 2024.

Nawal Ouzren, CEO of Sensorion, said: “In the first half of 2024, Sensorion has made steady positive progress and achieved several key milestones in its development plan. Most notably, we have made significant regulatory and clinical progress with SENS-501, our most advanced gene therapy program. After receiving the green light from European regulators in January 2024, I am pleased to announce that the first patient has been recruited and injected into the study. We look forward to keeping you updated on the progress of this program in the coming months.